The past, current and future trends in DNA vaccine immunisations

Hasson, Sidgi S.; Al-Busaidi, Juma Khalifa Zayid; Sallam, Talal A

doi:10.1016/s2221-1691(15)30366-x

Cited by 91 publications

(56 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the production of IgG2a antibodies is associated with the establishment of a Th1-type response, whereas the IgG1 subtype is related to a Th2-type response, ELISA assays were performed to quantify the specific anti-SLA and anti-HisAK70 polyprotein humoral responses in the groups. It is noteworthy that all mice (vaccinated and control groups) showed negative anti-SLA or anti-HisAK70 antibody titres after immunization (data not shown), thus confirming the low humoral immunogenicity of the vaccine [42,43]. However, at 14 weeks post infection with L. amazonensis, the specific anti-SLA IgG2a response increased significantly in HisAK70-immunized animals, confirming the development of a Th1-biased immune response, which is consistent with the development of a specific antileishmanial response in these animals ( Figure 6).…”

Section: Specific Humoral Responsementioning

confidence: 65%

Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice

et al. 2019

View full text Add to dashboard Cite

Leishmania amazonensis is the aetiological agent of a broad spectrum of leishmaniosis in South America. It can cause not only numerous cases of cutaneous leishmaniosis but also diffuse cutaneous leishmaniosis. Considering the diversity of parasite species causing different forms of the disease that coexist in the same region, it is desirable to develop a vaccine capable of eliciting cross-protection. We have previously described the use of HisAK70 DNA vaccine for immunization of mice to assess the induction of a resistant phenotype against Leishmania major and infantum infections. In this study, we extended its application in the murine model of infection by using L. amazonensis promastigotes. Our data revealed that 14 weeks post-infection, HisAK70-vaccinated mice showed key biomarkers of protection, such as higher iNOS/arginase activity, IFN-γ/IL-10, IFN-γ/IL-4, and GM-CSF/IL-10 ratios, in addition to an IgG2a-type response when compared to the control group. These findings correlated with the presentation of lower footpad swelling and parasite burdens in the immunized compared to the control mice. Overall, this study suggests that immunization with HisAK70 may be considered a suitable tool to combat leishmaniosis as it is able to induce a potent cellular immune response, which allows to control the infection caused by L. amazonensis.

show abstract

Section: Specific Humoral Responsementioning

confidence: 65%

Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The effectiveness of DNA vaccines has been demonstrated in several animal models and is a promising therapy against several human diseases, including cancer. Although there are advantages to DNA immunization, a reduced level of immunogenicity has been identified as an impediment for their efficacy [ 129 ]. Thus, it is necessary to obtain an adequate adjuvant to overcome this limitation.…”

Section: In Vivo Studiesmentioning

confidence: 99%

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

et al. 2017

View full text Add to dashboard Cite

For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma includes about 80 species of mushrooms, of which several have been used for centuries in traditional Asian medicine for their medicinal properties, including anticancer and immunoregulatory effects. Numerous bioactive compounds seem to be responsible for their healing effects. Among the approximately 400 compounds produced by Ganoderma spp., triterpenes, peptidoglycans and polysaccharides are the major physiologically-active constituents. Ganoderma anticancer effects are attributed to its efficacy in reducing cancer cell survival and growth, as well as by its chemosensitizing role. In vitro and in vivo studies have been conducted in various cancer cells and animal models; however, in this review, we focus on Ganoderma's efficacy on breast cancers. Evidence shows that some species of Ganoderma have great potential as a natural therapeutic for breast cancer. Nevertheless, further studies are needed to investigate their potential in the clinical setting and to translate our basic scientific findings into therapeutic interventions for cancer patients.

show abstract

“…Vaccine platforms such as the measles vector, modified vaccine Ankara vector, Chimpanzee adenovirus or cytomegalovirus vectors should be explored. Rationally designed subunit vaccines, RNA based vaccines (Scorza and Pardi, 2018 ) and DNA vaccines (Hasson et al, 2015 ) are other possible platform approaches.…”

Section: Rna Virus Research In Indiamentioning

confidence: 99%

Position Paper on Road Map for RNA Virus Research in India

2018

View full text Add to dashboard Cite

The Indian subcontinent with its population density, climatic conditions, means of subsistence, socioeconomic factors as well as travel and tourism presents a fertile ground for thriving of RNA viruses. Despite being pathogens of huge significance, there is very little focus on research into the biology and pathogenesis of RNA viruses in India. Studies on epidemiology and disease burden, risk factors, the immune response to RNA viruses, circulating virus strains and virus evolution, animal models of disease, antivirals and vaccines are strikingly absent. Emerging RNA viruses such as Zika virus, Nipah virus and Crimean-Congo haemorrhagic fever virus are a matter of grave concern to India. Here we summarize the outcome of the India|EMBO symposium on “RNA viruses: immunology, pathogenesis and translational opportunities” organized at Faridabad, National Capital Region, India, on March 28–30, 2018. The meeting focused on RNA viruses (non-HIV), and both national and international experts on RNA viruses covered topics ranging from epidemiology, immune response, virus evolution and vaccine trials concerning RNA viruses. The aim of the symposium was to create a road map for RNA virus research in India. Both concrete and tentative ideas pointing towards short-term and long-term goals were presented with recommendations for follow-up at government level.

show abstract

The past, current and future trends in DNA vaccine immunisations

Cited by 91 publications

References 95 publications

Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice

Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

Position Paper on Road Map for RNA Virus Research in India

Contact Info

Product

Resources

About